(56) **References Cited**

U.S. PATENT DOCUMENTS

5,662,883	A	9/1997	Bagchi et al.	
5,716,642	A	2/1998	Bagchi et al.	
5,770,181	A	6/1998	Kirkland	
5,902,816	A	5/1999	Viner	
5,929,093	A *	7/1999	Pang et al.	514/332
6,007,845	A	12/1999	Domb et al.	
6,117,454	A	9/2000	Kreuter et al.	
6,355,271	B1	3/2002	Bell et al.	
6,395,029	B1	5/2002	Levy et al.	
6,656,505	B2	12/2003	Kundu et al.	
6,815,543	B1	11/2004	Bernardelli	
6,861,068	B2	3/2005	Ng et al.	
6,881,745	B2	4/2005	Hayes et al.	
7,037,528	B2	5/2006	Kipp et al.	
7,081,161	B2	7/2006	Genge et al.	
7,282,194	B2	10/2007	Sung et al.	
7,300,670	B2	11/2007	Venus et al.	
7,387,792	B2	6/2008	Hirsh et al.	
7,390,384	B2	6/2008	Fang et al.	
2003/0073619	A1	4/2003	Mahato et al.	
2004/0022820	A1	2/2004	Anderson	
2004/0256749	A1	12/2004	Chaubal et al.	
2004/0266890	A1	12/2004	Kipp et al.	
2005/0106257	A1	5/2005	Albayrak	
2005/0113489	A1	5/2005	Baran, Jr. et al.	
2005/0118108	A1	6/2005	Cowan et al.	
2005/0220888	A1	10/2005	Putcha et al.	
2006/0063662	A1	3/2006	Hata et al.	
2006/0183777	A1	8/2006	Huang et al.	
2006/0216353	A1	9/2006	Liversidge et al.	
2007/0093518	A1 *	4/2007	Wetherell et al.	514/290
2007/0134339	A1	6/2007	Jenkins et al.	
2007/0190160	A1	8/2007	Turos et al.	
2008/0145439	A1	6/2008	Lobl et al.	
2008/0241256	A1	10/2008	Kuhn	
2009/0263491	A1	10/2009	Kreuter et al.	
2009/0281144	A1 *	11/2009	Cabell et al.	514/332
2009/0304720	A1	12/2009	Kreuter et al.	

FOREIGN PATENT DOCUMENTS

WO	9841188		9/1998
WO	0163362		8/2001
WO	0232402		4/2002
WO	2004073033		8/2004
WO	2005123581		12/2005
WO	2007/001355	A2	1/2007
WO	2007/084460	A2	7/2007
WO	2009114298		9/2009

OTHER PUBLICATIONS

Munavalli et al. (Heterocycles 1986, 24(7); 1883-1892).*

Thiermann et al. (International Journal of Pharmaceutics (1996), 137; p. 167-176).*

Chaumeil, J.C., Methods and Findings in Experimental and Clinical Pharmacology, Apr. 1998, vol. 20, No. 3, pp. 211-215.*

Garner et al. Journal of Pharmaceutical Sciences, vol. 91, Issue 1 , pp. 32-40.*

Choi, International Journal of Mineral Processing vol. 74, Supplement 1, Dec. 10, 2004, pp. S165-S172.*

Chemistry and Industry; Applied Chemistry; Nigel Freestone; Nov. 7, 2005 (4 pgs).

Chemistry and Industry; New Drug Delivery Systems; Alexander T. Florence; Dec. 20, 1993 (7 pgs).

Advanstar Communications, Inc.; Pharmaceutical Technology; Vivek Kharb; Meenakshi Bhatia; Harish Dureja; Deepak Kaushik; Feb. 1, 2006 (11 pgs).

Advanstar Communications, Inc.; Pharmaceutical Technology Europe; Magdalene Radtke; Eliana B. Souto; Rainer H. Muller; Apr. 1, 2005 (4 pgs).

Dennison, et al. "Corticosteroids in rheumatoid arthritis," British Medical Journal vol. 316, pp. 789-790 (1998).

Kenalog® Creams Triamcinolone Acetonide Cream USPO.025%, 0.1 %,0.5% (Online) http://dar1ymed.n1m.nih.gOY1dai1ymed/fda/fdaDrugXsl.cfm?id=1872&type=disp1ay; retrieved Jun. 21, 2008 (8 pages).

D. Farcasiu, et al. "Evaluation of hydrogen bonding by C-13NMR" Catalysis Letters 31 (1995) 351-358.

Praetorius, et al., "Engineered Nanoparticles in Cancer Therapy," Recent Patents on Drug Delivery & Formation 2007,vol. 1 No. 1, pp. 37-51.

Biosante Pharmaceuticals, "Hormone Therapy-A Multi-Billion Dollar Market," Investor Fact Sheet Sep. 2007; www.biosantepharma.com; (2 pages).

T.Welzel, et al., "Transfection of Cells With Custom-made Calcium Phosphate Nanoparticles Coated With DNA"; The Royal Society of Chemistry 2004; J. Mater. Chem. 2004, 14, pp. 2213-2217.

S. Bisht, et al., "pDNA Loaded Calcium Phosphate Nanoparticles: Highly Efficient Non-Viral Vector for Gene Delivery"; International Journal of Pharmaceutics 288 (2005), pp. 157-168.

T.Liu, et al., "Calcium Phosphate Nanoparticles As a Novel Nonviral Vector for Efficient Transfection of DNA in Cancer Gene Therapy"; Cancer Biotherapy & Radiopharmaceuticls, vol. 20, No. 2, 2005, pp. 141-150.

A. Brioschi, et al, "Solid Lipid Nanoparticles: Could They Help . . . "; Neurological Research 2007, vol. 29, Apr. 2007; pp. 324-330.

M. Nahar, et al, "Functional Polymeric Nanoparticles: An Efficient . . . "; Critical Reviews™ In Therapeutic Drug Carrier Systems, 23(4):259-318 (2006); Begell House Inc., http://begellhouse.com; downloaded Sep. 18, 2009 from IP 129.162.1.41 by Celia Frausto.

International Search Report and Written Opinion dated Nov. 23, 2009 issued in related International Patent Application No. PCT/US0959386.

U.S. Office Action dated Dec. 9, 2010 issued in related U.S. Appl. No. 11/555,995.

Digiovanni, Jr., M.D., Cleto, Domestic Terrorism With Chemical or Biological Agents: Psychiatric Aspects, Am J Psychiatry, Oct. 1999, pp. 1500-1505, vol. 156:10.

D'Mello, G.D., Behavioural Toxicity of Anticholinesterases in Humans and Animals—A Review, Human & Experimental Toxicology, 1993, pp. 3-7, vol. 12.

Eyer, et al., Oximes—Chapter 15, Chemical Warfare Agents: Toxicology and Treatment, 2007, pp. 305-329, 2nd Edition.

Jager, et al., Toxicity of Diacetyl Monoxime and of Pyridine-2-Aldoxime Methiodide in Man, Bull John Hopkins Hosp., 1958, pp. 203-211, vol. 102.

Jamal, Goran A., Long term neurotoxic effects of organophosphate compounds, Adverse Drug React. Toxicol. Rev, 1995, pp. 85-99, vol. 14(2).

Marrs et al., Chemical Warfare Agents: Toxicology and Treatment Second Edition, 2007, pp. all. Table of contents attached electronically, physical book is cited and supplied in U.S. Appl. No. 12/702,095 which was mailed to USPTO Oct. 8, 2010.

McDonough, et al., Behavioral Correlates of Soman-Induced Neuropathology: Deficits in DRL Acquisition, Neurobehavioral Toxicology and Teratology, 1986, pp. 179-187, vol. 8.

U.S. Office Action dated Jun. 25, 2008 issued in U.S. Appl. No. 11/555,995, 23 pages.

U.S. Office Action dated Nov. 28, 2008 issued in U.S. Appl. No. 11/555,995, 8 pages.

Radic, et al., "Evaluation of HI-6 oxime: potential use in protection of human acetylcholinesterase inhibited by antineoplastic drug irinotecan and its cyto/genotoxicity in vitro," Acta Biochimica Polonica vol. 54 No. 3/2007, 583-593, Aug. 23, 2007.

Stojiljkovic, et al., "Pryidinum Oximes: Rationale for their Selection as casual Antidotes against Organophosphate Poisonings and current solutions for auto-injectors," Arh Hig Toksikol 2006, 57:435-443.

International Search Report and Written Opinion of the ISA issued in PCT/US09/35539 dated Jul. 17, 2009 (8 pgs).

International Search Report and Written Opinion of the ISA issued in PCT/US09/52457 dated Oct. 6, 2009 (9 pgs).

Luo et al, "An in Vitro Comparative Study on the Reactivation of Nerve Agent-Inhibited Guinea Pig and Human Acetylcholinesterases by Oximes"; Biochemistry 2007, 46, pp. 11771-11779.